Navigation Links
Hepatitis C virus genotype 1 is most prevalent worldwide
Date:7/27/2014

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. Genotype 3, at just over 54 million cases, is the next most prevalent, followed by genotypes 2, 4, 6, and 5.

Despite efforts to control HCV, it remains one of the most prevalent diseases globally, with up to 150 million patients living with chronic infection according to the World Health Organization (WHO). Previous research shows that chronic HCV leads to the development liver cirrhosis, hepatocellular carcinoma (HCC) or liver cancer, liver failure and death. WHO reports that 350,000 to 500,000 deaths each year are caused by liver diseases related to HCV.

"While the HCV infection rate is decreasing in developed countries, deaths from liver disease secondary to HCV will continue increasing over the next 20 years," explains lead co-author Dr. Jane Messina with the University of Oxford in the U.K. "Understanding the global trends in the genetic makeup of HCV is the focus of our study and imperative in developing new treatment strategies that may save millions of lives around the world."

Researchers identified 1,217 medical studies between 1989 (the year HCV was discovered) and 2013 that reported HCV genotypes. The data were then combined with HCV prevalence estimates from the WHO Global Burden of Disease project. Roughly 90% of the global population, representing 117 countries was included in this study.

Analysis shows that HCV genotype 1 is the most prevalent at 46% of all HCV cases, followed by genotype 3 at 30%; genotypes 2, 4, and 6 with a combined total of 23% and genotype 5 at less than 1%. Researchers highlight that genotypes 1 and 3 are most dominant regardless economic status, but found lower-income countries had larger concentrations of genotypes 4 and 5.

Dr. Eleanor Barnes with the University of Oxford adds: "The testing of new therapeutics is still dependent upon knowledge of viral genotype. Non-genotype 1 HCV, comprises more than half of all HCV cases. Our study provides evidence of genotype prevalence for specific countries and regions that will help improve access to new viral therapies to combat HCV."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert  

Related biology news :

1. The search is on for a hepatitis B drug, thanks to a million dollars in NIH grants to SLU
2. New technique brings us closer to HIV and Hepatitis C vaccines
3. EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
4. MassBiologics receives orphan drug status from FDA for hepatitis C treatment
5. Scripps Research Institute scientists achieve most detailed picture ever of key part of hepatitis C
6. Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol
7. Mount Sinai researchers develop first successful laboratory model for studying hepatitis C
8. New Loyola study on hepatitis C virus entry factor
9. Vitamin D deficiency may help spread of hepatitis B throughout liver
10. New mouse viruses could aid hepatitis research
11. HIV sufferers need hepatitis safeguards
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hepatitis C virus genotype 1 is most prevalent worldwide
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... Feb. 3, 2017  Texas Biomedical Research Institute announced that ... Larry Schlesinger as the Institute,s new President and CEO. ... May 31, 2017. He is currently the Chair of the ... Center for Microbial Interface Biology at Ohio State University. ... new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the "Nanobiotechnology ... ... separate comprehensive analytics for the US, Japan , ... and forecasts are provided for the period 2015 through 2022. Also, ... and analytics are derived from primary and secondary research. This report ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
Breaking Biology Technology: